Lack of Consensus for Margin Width Leads to Additional Breast Cancer Surgery
the Cancer Therapy Advisor take:
According to researchers from the University of Wisconsin School of Medicine and Public Health, the lack of consensus or established guidelines on the sufficient distance of excision between the tumor and the edge of surrounding tissue during breast cancer surgery has lead to variable excision rates and additional operations, by as much as 60%.
The authors of a study published recently in JAMA Surgery used the National Cancer database to analyze data from 316,114 patients who underwent breast cancer surgery in the United States between 2004 and 2010 (patients who were initially treated with chemotherapy or excision biopsy were excluded).
Seventy-six percent of these patients had a single lumpectomy, and of those patients, almost 24% had at least one additional operation for their breast cancer (62% with a completion lumpectomy; 38% with a complete mastectomy). It is hoped that the results from this analysis will help to inform patients about the risk for repeat surgery for breast cancer, and will also spur guidelines that will standardize tumor margin and help reduce local recurrence rates.
Additional breast cancer operations can cause the patient added distress, cost, and delays to adjuvant therapy, so avoiding these often unnecessary surgeries may ultimately improve patient outcome and prevent wasted health care resources.
Lack of consensus on distance of excision between tumor and tissue has lead to variable excision rates.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib
- Opinion: Understanding the FDA's Take on Cannabidiol
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma